Renoprotection with and without blood pressure reduction
Authors:
- Gozewijn Dirk LavermanGLGozewijn Dirk Laverman
- Steen AndersenSASteen Andersen
- Peter RossingPRPeter Rossing
- Gerjan NavisGNGerjan Navis
- Dick De ZeeuwDZDick De Zeeuw
- Hans-Henrik ParvingHPHans-Henrik Parving
- 1 April 2005
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 67 (94) , S54-S59
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Optimal dose of losartan for renoprotection in diabetic nephropathyNephrology Dialysis Transplantation, 2002
- Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuriaAmerican Journal of Kidney Diseases, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Proteinuria as a modifiable risk factor for the progression of non-diabetic renal diseaseKidney International, 2001
- The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretionJournal of the Renin-Angiotensin-Aldosterone System, 2001
- Angiotensin II antagonists for hypertension: are there differences in efficacy?American Journal of Hypertension, 2000
- The role of systemic hypertension in the progression of nondiabetic renal diseaseKidney International, 2000
- Renoprotective therapy: titration against urinary protein excretionThe Lancet, 1999
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993
- EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHYThe Lancet, 1983